5 David Einhorn NeuBase Therapeutics Trades
David Einhorn's position in NeuBase Therapeutics is currently worth $55.9 Thousand. That's 0.00% of their equity portfolio (37th largest holding). The investor owns 3.44% of the outstanding NeuBase Therapeutics stock. David Einhorn started to build up the position in NeuBase Therapeutics in Q3 2019 and continued to invest until Q2 2021. Since then they sold 1 shares. The investor's estimated purchase price is $294 Million, resulting in a loss of 100%.
Avg closing price
Price range
Sold 0.0% shares (-1 shares)
Q2 2023
Avg closing price
$57.69
Price range
$1.87
-
$82.40
Increased shares by 34.5% (+35 Thousand shares)
Q2 2021
Avg closing price
$2,209.21
Price range
$1,852.00
-
$2,936.00
Increased shares by 6.5% (+6.19 Thousand shares)
Q3 2020
Avg closing price
$3,262.72
Price range
$2,900.00
-
$3,884.00
Increased shares by 23.7% (+18.2 Thousand shares)
Q2 2020
Avg closing price
$3,347.37
Price range
$2,676.00
-
$4,604.00
New holding (+76.9 Thousand shares)
Q3 2019
Avg closing price
$1,757.18
Price range
$3.15
-
$2,636.00
